Serum Half-Life of the Tumor Marker CA 125 During Induction Chemotherapy as a Prognostic Indicator for Survival in Ovarian Carcinoma

References

• National Board of Health and Welfare. The Cancer Registry. Cancer incidence in Sweden. Allmanna forlaget AB, StockholmSweden 1985
   Google Scholar
• Annual report on the results of treatment in gynecological cancer, F Pettersson, P Kolstad, H Ludwig, H Ulfelder. Radiumhem-met, StockholmSweden 1985; vol 19
   Google Scholar
• Bertelsen K, Jakobsen A, Andersen J E, et al. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol 1987; 28: 161–9
   PubMed Web of Science ®Google Scholar
• Gruppo Interegionale Cooperative Oncologico Gine-cologia. Randomised comparison of cisplatin with cy-clophosphamide/cisplatin and with cyclophosphamide/ doxorubicin/cisplatin in advanced ovarian cancer. Lancet August, 1987; 15: 353–9
   Google Scholar
• Shelley W E, Carmichael J C, Brown L B, et al. Adria-mycin and cisplatin in the treatment of stage III and IV epithelial ovarian carcinoma. Gynecol Oncol 1988; 29: 208–21
   Google Scholar
• Trope C. Melphalan with and without doxorubicin in advanced ovarian cancer. Obstet Gynecol 1987; 70: 582–6
   PubMed Web of Science ®Google Scholar
• Bast R C, Jr, Feeney M, Lazarus H, Nadler L M, Colvin R B, Knapp R C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331–7
   PubMed Web of Science ®Google Scholar
• Bast R C, Jr, Klug T L, St. John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883–7
   PubMed Web of Science ®Google Scholar
• Peto R, Pike M C, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1–39
   PubMed Web of Science ®Google Scholar
• Tarone R E. Tests for trend in life table analysis. Bio-metrika 1975; 62: 679–82
   Google Scholar
• Jacobs I, Bast R C, Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989; 4: 1–12
   PubMed Web of Science ®Google Scholar
• Touitou Y, Bogdan A. Tumor markers in non-malignant diseases. Eur J Clin Oncol 1988; 24: 1083–91
   PubMedGoogle Scholar
• Redman C WE, Jones S R, Luesley D M, et al. Peritoneal trauma releases CA125?. Br J Cancer 1988; 58: 502–4
   Google Scholar
• Talbot R W, Jacobsen D J, Nagorney D M, Malkasian G D, Ritts R E. Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer. Surg Gynecol Obstet 1989; 168: 407–12
   PubMedGoogle Scholar
• Atack D B, Nisker J A, Allen H H, Tustanoff E R, Levin L. CA125 surveillance and second-look laparotomy in ovarian carcinoma. Am J Obstet Gynecol 1986; 154: 287–9
   PubMed Web of Science ®Google Scholar
• Berek J S, Knapp R C, Malkasian G D, et al. CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol 1986; 67: 685–9
   PubMed Web of Science ®Google Scholar
• Meier W, Stieber P, Fateh-Moghadam A, Eiermann W, Hepp H. CA 125-serum levels and histological findings at second-look laparotomy in ovarian cancer patients. Geburtshilfe Frauenheilkd 1988; 48: 331–3
   Google Scholar
• Mobus V, Kreienberg G, Crombach G, et al. Evaluation of CA 125 as a prognostic and predictive factor in ovarian cancer. J Tumor Marker Oncol 1988; 3: 251–8
   Google Scholar
• Niloff J M, Bast R C, Jr, Schaetzl E M, Knapp R C. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol 1985; 151: 981–6
   PubMed Web of Science ®Google Scholar
• van der Burg M EL, Lammes F B, van Putten W LJ, Stoter G. Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol 1988; 30: 307–12
   PubMed Web of Science ®Google Scholar
• Lavin P T, Knapp R C, Malkasian G, Whitney C W, Berek J C, Bast R C, Jr. CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol 1987; 69: 223–7
   PubMedGoogle Scholar
• Lahousen M, Stettner H, Pickel H, Urdl W, Purstner P. The predictive value of a combination of tumor markers in monitoring patients with ovarian cancer. Cancer 1987; 60: 2228–32
   PubMed Web of Science ®Google Scholar